Immunological transformations in the recipient of grafted allogeneic human bone

• Published in: Archives of orthopaedic and trauma surgery Vol. 116; no. 3; pp. 143 - 150
• Main Authors: HOFMANN, G. O, FALK, C, WANGEMANN, T
• Format: Journal Article
• Language: English
• Published: Berlin Springer 1997; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antigens; Biological and medical sciences; Bone Transplantation - immunology; Bone Transplantation - methods; Female; Follow-Up Studies; Graft Survival - immunology; Humans; Immunology; Isoantibodies - analysis; Lymphocytes - immunology; Male; Medical sciences; Middle Aged; Orthopedic surgery; Postoperative Complications - epidemiology; Postoperative Complications - immunology; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Survival Rate; Tissue and Organ Procurement; Tissue Banks; Transplantation, Homologous; Human; Immunological surveillance; Treatment; Diseases of the osteoarticular system; Homograft; Graft; Bone defect; Recipient; Spongious bone; Technique
• ISSN: 0936-8051; 1434-3916
• DOI: 10.1007/BF00426063

Twenty-one patients received allogeneic human bone grafts following deep freezing according to various orthopaedic indications. The HLA antigens of all donors and recipients had been determined preoperatively, and grafting was performed without any respect to the HLA match. The immunological follow-up of the recipients was managed by two different methods: MLC (mixed lymphocyte culture) and MAILA (monoclonal antibody-specific immobilisation of lymphocyte antigens). No immunosuppression was performed. The follow-up lasted up to 6 years. Allogeneic grafting of human cancellous bone induces specific immunological reactions in the recipient. The consequences of these observations are: (1) allogeneic bone grafting may induce second-set reactions following subsequent blood transfusion, tissue grafting or organ transplantation; (2) transplantation of fresh, perfused, vascularised allogeneic bone or joint may become a therapeutic approach in the near future. Then the employment of standard immunosuppressive protocols will be mandatory in order to fight acute rejection of the graft.